Xenon Pharmaceuticals Inc. (XENE): Price and Financial Metrics

Xenon Pharmaceuticals Inc. (XENE): $39.88

0.43 (-1.07%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

D

Add XENE to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#263 of 362

in industry

XENE Price/Volume Stats

Current price $39.88 52-week high $50.99
Prev. close $40.31 52-week low $27.99
Day low $39.01 Volume 362,800
Day high $41.26 Avg. volume 402,991
50-day MA $44.92 Dividend yield N/A
200-day MA $39.69 Market Cap 3.01B

XENE Stock Price Chart Interactive Chart >


Xenon Pharmaceuticals Inc. (XENE) Company Bio


Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing differentiated therapeutics for orphan indications in Canada. The company was founded in 1996 and is based in Burnaby, Canada.


XENE Latest News Stream


Event/Time News Detail
Loading, please wait...

XENE Latest Social Stream


Loading social stream, please wait...

View Full XENE Social Stream

Latest XENE News From Around the Web

Below are the latest news stories about XENON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate XENE as an investment opportunity.

Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

VANCOUVER, British Columbia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 9,846,157 common shares, which includes 1,384,615 shares sold upon the full exercise of the underwriters’ option to purchase additional shares, and pre-funded warrants to purchase up to 769,230 common shares. The common shares were offered at a public offering

Yahoo | December 4, 2023

After losing 5.2% in the past year, Xenon Pharmaceuticals Inc. (NASDAQ:XENE) institutional owners must be relieved by the recent gain

Key Insights Significantly high institutional ownership implies Xenon Pharmaceuticals' stock price is sensitive to...

Yahoo | December 4, 2023

Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)

VANCOUVER, British Columbia, Dec. 02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will provide updates on its neurology programs at the Annual Meeting of the American Epilepsy Society (AES 2023). Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer, stated, “Xenon will have another strong presence at AES this year, with many presentations and activities aimed at raising awareness about our XEN1101

Yahoo | December 2, 2023

Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering

VANCOUVER, British Columbia, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE) (“Xenon”), a neurology-focused biopharmaceutical company, today announced the pricing of its upsized underwritten public offering of 8,461,542 common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 769,230 common shares pursuant to its existing shelf registration statement. The common shares are being offered at a public offering price of $32.50

Yahoo | November 30, 2023

Xenon Pharmaceuticals Announces Proposed Public Offering

VANCOUVER, British Columbia, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE) (“Xenon”), a neurology-focused biopharmaceutical company, today announced that it has commenced an underwritten public offering of $225.0 million of its common shares and, in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase common shares, pursuant to its existing shelf registration statement. All of the common shares and pre-funded warrants in this off

Yahoo | November 29, 2023

Read More 'XENE' Stories Here

XENE Price Returns

1-mo -9.36%
3-mo -11.77%
6-mo 20.30%
1-year 1.24%
3-year 109.45%
5-year 330.67%
YTD -13.42%
2023 16.81%
2022 26.22%
2021 103.12%
2020 17.32%
2019 107.77%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!